<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39467241</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0040-3660</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Terapevticheskii arkhiv</Title><ISOAbbreviation>Ter Arkh</ISOAbbreviation></Journal><ArticleTitle>[Polymorphism of RAAS genes in patients with COVID-19: comparison with frequency in population and relationship with severity of course].</ArticleTitle><Pagination><StartPage>872</StartPage><EndPage>878</EndPage><MedlinePgn>872-878</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.26442/00403660.2024.09.202849</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Evaluation of genes polymorphisms frequencies of angiotensinogen (AGT), angiotensin converting enzyme type 1 (ACE1) and angiotensin II receptors type 1 (AGTR1) and type 2 (AGTR2) in patients admitted with coronavirus disease (COVID-19) and its association the severity of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The study included 100 patients admitted to the hospital with a laboratory-confirmed diagnosis of COVID-19. All patients were identified with alleles and genotypes of polymorphic markers rs4762 of the AGT gene, rs1799752 of the ACE1 gene, rs5186 of the AGTR1 gene and rs1403543 of the AGTR2 gene. The frequencies of each polymorphisms were compared with population. Statistical processing was performed using the Statistica 8.0 software package.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In evaluated cohort there was higher frequency of D-allele ACE1 rs1799752 compared to population. Depending on the availability of criteria for the severity of coronavirus infection, 44 (44%) patients were diagnosed with severe, 56 (56%) with moderate course. The groups did not significantly differ in age, gender, cardiovascular risk factors and comorbid pathology. In the groups with severe and moderate course, the same distribution of genotypes and alleles of AGT rs4762, AGTR2 rs1403543 and ACE1 rs1799752 was revealed. For the I/D alleles of the ACE1 rs1799752 gene, a significant deviation from the papulation was found in both the group of severe and moderate COVID-19. In the group with a severe course of the disease, a higher frequency of the mutant C-allele of the AGTR1 rs5186 gene was detected. In the same group, a deviation in the frequency ratio of A and C of the AGTR1 rs5186 alleles from Hardy-Weinberg Equilibrium was found. When calculating the risk of severe COVID-19 in the presence of the C-allele compared with the A-allele, an odds ratio 2.092 (95% confidence interval 1.066-4.108) was obtained.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The data obtained suggest that the genes polymorphisms of the components of renin-angiotensin-aldosterone system, namely D-allele of ACE1 rs1799752 and C-allele of AGTR1 rs5186, may make it possible to identify groups of patients predisposed to the development of more severe COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bragina</LastName><ForeName>A E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-2699-1610</Identifier><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodionova</LastName><ForeName>Y N</ForeName><Initials>YN</Initials><Identifier Source="ORCID">0000-0003-3461-6703</Identifier><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogibenina</LastName><ForeName>E S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-2129-818X</Identifier><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fomin</LastName><ForeName>A S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0009-0003-6833-295X</Identifier><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podzolkov</LastName><ForeName>V I</ForeName><Initials>VI</Initials><Identifier Source="ORCID">0000-0002-0758-5609</Identifier><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University).</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Ter Arkh</MedlineTA><NlmUniqueID>2984818R</NlmUniqueID><ISSNLinking>0040-3660</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044140">Receptor, Angiotensin, Type 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044139">Receptor, Angiotensin, Type 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>11002-13-4</RegistryNumber><NameOfSubstance UI="D000808">Angiotensinogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C544065">AGTR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="C488034">ACE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C534931">AGT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000654624">AGTR2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012084" MajorTopicYN="Y">Renin-Angiotensin System</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044140" MajorTopicYN="Y">Receptor, Angiotensin, Type 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044139" MajorTopicYN="Y">Receptor, Angiotensin, Type 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000808" MajorTopicYN="Y">Angiotensinogen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="Y">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText>Цель. Оценить частоты полиморфизмов генов ангиотензиногена (АТГ), ангиотензинпревращающего фермента 1-го типа (АПФ 1) и рецепторов ангиотензина II 1-го (АТ 1) и 2-го (АТ 2) типов у больных, госпитализированных с коронавирусной инфекцией (COVID-19), и их связи с тяжестью течения болезни, вызванной коронавирусом тяжелого острого респираторного синдрома 2. Материалы и методы. В исследование включены 100 пациентов, госпитализированных с лабораторно подтвержденным диагнозом COVID-19. Всем больным идентифицировали аллели и генотипы полиморфных маркеров rs4762 гена АТГ, rs1799752 гена АПФ 1, rs5186 гена АТ 1 и rs1403543 гена АТ 2. Частоты каждого полиморфизма сопоставляли с популяционными. Статистическую обработку проводили с использованием пакета программ Statistica 8.0. Результаты. В обследованной когорте выявлена более высокая частота D-аллеля АПФ 1 rs1799752, чем в популяции. В rs1799752 в зависимости от наличия критериев тяжести течения COVID-19 у 44 (44%) пациентов установлено тяжелое течение, у 56 (56%) – среднетяжелое. Группы достоверно не различались по возрасту, половому составу, факторам сердечно-сосудистого риска и коморбидной патологии. В группах с тяжелым и среднетяжелым течением выявлено одинаковое распределение генотипов и аллелей АТГ rs4762, AТ 2 rs1403543 и АПФ 1 rs1799752. Для I/D аллелей гена АПФ 1 rs1799752 обнаружено достоверное отклонение от популяционных показателей в группах тяжелого и среднетяжелого течения СOVID-19. В группе с тяжелым течением заболевания выявлена более высокая частота мутантного С-аллеля гена AТ 1 rs5186. В этой же группе обнаружено отклонение частотного соотношения А-аллеля и С-аллеля AТ 1 rs5186 от равновесия Харди–Вайнберга. При расчете риска тяжелого течения COVID-19 при наличии С-аллеля по сравнению с А-аллелем получено отношение шансов 2,092 (95% доверительный интервал 1,066–4,108). Заключение. Приведенные данные позволяют предположить, что полиморфизм генов – компонентов ренин-ангиотензин-альдостероновой системы, а именно D-аллель АПФ 1 rs1799752 и C-аллель AТ 1 rs5186, может позволить выделить группы пациентов, предрасположенных к развитию более тяжелой COVID-19.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiotensin II receptors type 1</Keyword><Keyword MajorTopicYN="N">angiotensin II receptors type 2</Keyword><Keyword MajorTopicYN="N">angiotensin converting enzyme type 1</Keyword><Keyword MajorTopicYN="N">angiotensinogen</Keyword><Keyword MajorTopicYN="N">coronavirus disease</Keyword><Keyword MajorTopicYN="N">gene polymorphism</Keyword><Keyword MajorTopicYN="N">renin-angiotensin-aldosterone system</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>16</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39467241</ArticleId><ArticleId IdType="doi">10.26442/00403660.2024.09.202849</ArticleId></ArticleIdList></PubmedData></PubmedArticle>